Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00078713" target="_blank" >RIV/00023001:_____/19:00078713 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/19:10402051 RIV/00064203:_____/19:10402051

Výsledek na webu

<a href="https://reader.elsevier.com/reader/sd/pii/S1567568819300595?token=9A029E9726EA063036DB8F6689F7A32D908EF25160CD28DE1962B2A585ACFC84A0588C29797C58FFB1F1AD2237C31C9C" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S1567568819300595?token=9A029E9726EA063036DB8F6689F7A32D908EF25160CD28DE1962B2A585ACFC84A0588C29797C58FFB1F1AD2237C31C9C</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.036" target="_blank" >10.1016/j.atherosclerosissup.2019.08.036</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a)

Popis výsledku v původním jazyce

Background: Lipoprotein apheresis (LA) is a well-established therapy for lowering lipid levels in serious cases of dyslipidaemia, including high levels of lipoprotein(a) [Lp(a)]. This method lowers both LDL cholesterol and Lp(a) by more than 60% in most of patients; however, because randomized clinical studies could be extremely difficult, also other markers of the effect of this procedures on vascular health are of importance. Therefore, in addition to changes in plasma lipids and Lp(a) during LA, we also analysed the response of biomarkers associated with vascular integrity: small non-coding microRNAs (miRNAs). Materials and methods: We analysed the changes in miRNAs in two women (age 70 and 72 years) with clinically manifest extensive and progressive atherosclerotic disease and high levels of Lp(a) and with different clinical course who were treated by LA. In both women we analysed changes of 175 circulating plasma miRNAs using pre-defined serum/plasma focus panels at the beginning of and one year after the therapy. Results: In addition to reduced levels of plasma lipids and Lp(a), circulating plasma levels of miR-193a-5p; -215-5p; -328-3p; -130a-3p; -362-3p; -92b-3p decreased, and levels of miR-125a-5p; -185-5p; -106a-5p; -320b; -19a increased (all P &lt; 0.05) in both women. Moderate differences were found between both women with regard to the different course of atherosclerotic disease. Conclusions: Long-term LA substantially changes circulating plasma miRNAs associated with vascular integrity reflected different clinical course in both women. If confirmed, this approach could improve the assessment of the effectiveness of this therapy on an individual basis. (C) 2019 Elsevier B.V. All rights reserved.

Název v anglickém jazyce

Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a)

Popis výsledku anglicky

Background: Lipoprotein apheresis (LA) is a well-established therapy for lowering lipid levels in serious cases of dyslipidaemia, including high levels of lipoprotein(a) [Lp(a)]. This method lowers both LDL cholesterol and Lp(a) by more than 60% in most of patients; however, because randomized clinical studies could be extremely difficult, also other markers of the effect of this procedures on vascular health are of importance. Therefore, in addition to changes in plasma lipids and Lp(a) during LA, we also analysed the response of biomarkers associated with vascular integrity: small non-coding microRNAs (miRNAs). Materials and methods: We analysed the changes in miRNAs in two women (age 70 and 72 years) with clinically manifest extensive and progressive atherosclerotic disease and high levels of Lp(a) and with different clinical course who were treated by LA. In both women we analysed changes of 175 circulating plasma miRNAs using pre-defined serum/plasma focus panels at the beginning of and one year after the therapy. Results: In addition to reduced levels of plasma lipids and Lp(a), circulating plasma levels of miR-193a-5p; -215-5p; -328-3p; -130a-3p; -362-3p; -92b-3p decreased, and levels of miR-125a-5p; -185-5p; -106a-5p; -320b; -19a increased (all P &lt; 0.05) in both women. Moderate differences were found between both women with regard to the different course of atherosclerotic disease. Conclusions: Long-term LA substantially changes circulating plasma miRNAs associated with vascular integrity reflected different clinical course in both women. If confirmed, this approach could improve the assessment of the effectiveness of this therapy on an individual basis. (C) 2019 Elsevier B.V. All rights reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

<a href="/cs/project/NV17-28882A" target="_blank" >NV17-28882A: Genetické polymorfismy, MiRNA a vybrané bioindikátory aktivity - vzájemné vztahy při diagnostice a léčbě těžké familiární hypercholesterolemie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Atherosclerosis supplements

ISSN

1567-5688

e-ISSN

—

Svazek periodika

40

Číslo periodika v rámci svazku

December

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

5

Strana od-do

12-16

Kód UT WoS článku

000501345000003

EID výsledku v databázi Scopus

2-s2.0-85076126166